Paul Mola

President, CEO & Founder

Mr. Mola is the Chief Executive Officer and President of Roswell Biotechnologies, Inc., and a member of the company’s board of directors. He founded Roswell in 2014, bringing more than 20 years of life science industry leadership and executive experience to the company. Previously, Mr. Mola was Head of Global Solutions at Human Longevity, Inc., working with genome sequencing pioneer Craig Venter to establish international precision medicine partnerships. Prior to that, he spent over a decade at Life Technologies / Applied Biosystems (now part of ThermoFisher Scientific), the global leader in life science tools, and the historical market leader in DNA sequencing technology, where he was President of the Enterprise Genomic Solutions Business Unit and Head of Strategy and Chief of Staff for the Genetic Systems Division. In these roles, he managed strategy and international, large-scale business engagements for the entire DNA Sequencing Technology portfolio.

Mr. Mola received the Life Technologies’ “Game Changer” award, the company’s highest honor for work that transforms the company, for his accomplishments which included establishing the national genome sequencing program for the government of Saudi Arabia, driving the acquisition of the Ion Torrent sequencing platform, leading the commercialization of the SOliD sequencing platform, and developing the business strategy for the Genia sequencing platform (later acquired by Roche). Earlier in his career, Mr. Mola served in product development, sales, and marketing roles at Roche. Paul serves on the board of Biocom California, the association representing the California life science industry. Additionally, he is a member of the advisory councils to the Fleet Science Center and the San Diego State University Mission Valley Innovation District. He holds a post-graduate degree in Biotechnology and Business.

Barry Merriman

CSO & CoFounder

Barry is the Chief Science Officer of Roswell Biotechnologies, and a member of the company’s board of directors. He co-founded Roswell with Paul after they had worked closely for over a decade creating numerous major initiatives in genomics in both academia and private industry. Barry has more than 30 years of experience in scientific research and technology development, with deep expertise in DNA sequencing technology and associated applications. Previously, Dr. Merriman served as Vice President of Global Technology Assessment at Human Longevity, Inc., working directly with genome sequencing pioneer Craig Venter to create the technology stack for a comprehensive approach to precision medicine and precision oncology. Prior to that, at Life Technologies, Barry was Lead System Architect for Advanced DNA Sequencing Technology and Chief Science Officer of Enterprise Genomics Solutions Business. In those capacities, he architected the future sequencing technology roadmap for the company, including the programs resulting in the acquisition of Ion Torrent sequencing platform and engagement with the Genia sequencing platform (acquired by Roche).

He also architected population-scale genome sequencing programs globally, including the national program for the government of Saudi Arabia. For these works, Barry received the Life Technologies’ “Game Changer” award, the highest honor for work that transforms the company. Barry served on the faculty of UCLA for 20 years, leading interdisciplinary research spanning mathematics, physics, engineering, computer science, genetics and genomics. He has published extensively in scientific literature and is a highly regarded international lecturer in these fields. Barry has a PhD. in Applied Mathematics from the University of Chicago, as well as a B.S. in Mathematics and B.S. in Physics from the University of Washington.

Carl W. Fuller, PhD

Head of Roswell Innovation Lab

Carl has been working for more than 30 years with DNA polymerases, RNA polymerases and reverse transcriptases. He was directly involved in corporate efforts to produce complete sequencing systems such as the capillary electrophoresis system of Molecular Dynamics/Amersham, the SOLiD system of Applied Biosystems and the chip-based sequencers of Genia and Ion Torrent. Carl has served in senior and executive-level positions at Singular Genomics, Genia Technologies (now Roche), Life Technologies, GE healthcare and Amersham Biosciences. He has published over 70 issued patents and patent applications.

Isabel Sauerbrey, MSEL

Head of IT and Operations

With more than three decades' experience in information technology and operations, Isabel is responsible for implementing and supporting global business systems applications, such as finance, manufacturing, operations, general & administration and product development. Previously, she was Vice President of Operations and Information Technology at the San Diego Tourism Authority, where she provided direction and strategic leadership for all IT and operational initiatives. She has held numerous leadership positions with technology companies, including AST Computer, Rogerson Aircraft Corp., Motorola Broadband Communication Sector, and General Instruments.

John Tompkins

Head of Product Commercialization

John comes from Alveo Technologies where he was Executive Vice President of Engineering and Operations, and currently serves as an Advisor to Azolla, a synthetic biology start-up focused on clean tech. Prior to Alveo, John was Head of Program Management, PMO and New Product Introduction at Siemens Healthineers. John has a passion for the development of organizations and products that positively affect lives with the deployment of solutions that were the result of sound business strategy, effective product management, inspired product development, and thought-out operational design. He has a background in mechanical engineering, engineering design, and strategy.

Mike Nguyen

Head of Systems Integration

Mike comes to Roswell from Juno Diagnostics, where he was Principal Engineer and Head of Engineering. Previously, he was Head of Fluidics at Omniome, and Associate Director of Product Development at Plexium. Mike served in various research and development roles at Illumina, Alere, IntegenX, Caliper, and Molecular Dynamics. He has an extensive background in engineering, mechanical and fluidic system design, microfluidics, prototyping and fabrication, as well as assay development, sequencing technology, and DNA extraction, purification, and detection.

Jarrod Panza

JD Head of Corporate Development

Before Roswell, Jarrod served as Executive Vice President - Corporate Development and General Counsel at Acumen, Inc., a leading healthcare operations company. A seasoned executive in the life sciences industry, Jarrod was Head of Corporate Legal at the medical device company NuVasive, and Senior Corporate Counsel of M&A, Governance, and Securities at Life Technologies (now a part of Thermo Fisher). Jarrod has helped growth-stage companies deliver scalable and sustained commercial success and select and execute on strategic partnerships -- including $25B in M&A transactions in his nearly 20-year career.

Seth Stern, PhD

Vice President Core Technology R&D

Before joining Roswell, Seth served as a Principal Scientist and Research Fellow at Genapsys. Previously, among other positions, he was a Principal Scientist at IntegenX, and a Device Physicist at Intel. Seth is an experienced, hands-on molecular biologist and electrical engineer with an extensive knowledge of nucleic acid chemistry and applications. His specialties are invention and integration of molecular biology, electronics, and microfluidics into functional products, as well as trouble-shooting and optimization of molecular biology procedures.

Dan Salehi

Head of Intellectual Property

Dan brings extensive corporate and intellectual property experience in the life sciences to Roswell. His consulting practice focuses on start-up companies and new ventures. Previously, he was a Business Unit Lead at Life Technologies (now Thermo Fisher), where he was instrumental in the acquisition of Ion Torrent and managed a team of IP attorneys and professionals. Dan served over a decade at top-tier IP boutiques and an AM law 100 firms focusing on patent prosecution, portfolio management and patent litigation.

Hadi Abderrahim,
MD, PhD, MBA

Head of Systems Development

Before Roswell, Hadi led the strategy for healthcare and biomedical research at the Qatar Foundation. Previously, he had successfully established the Qatar Biobank and initiated the Qatar Genome project aimed at sequencing the majority of the country’s adult population. Hadi has more than 20 years' experience in human genetics and biomarker development, including senior-level positions at Merck Serono and Genset. As Head of Genetics and Biomarkers at Merck Serono, Hadi oversaw strategies for patient stratification in personalized medicine and established a central biobank based in Italy.

Bryan Rice, PhD

Head of Silicon Integration & Manufacturing Fellow

Prior to joining Roswell, Bryan was Vice President of Core Technology Research at Biological Dynamics, and Vice President of Technology Development at GlobalFoundries. He is an executive and technologist with a background in the semiconductor and biotechnology fields. Bryan has extensive experience leading research and development organizations in the transition from proof-of-concept to manufacturing for a novel technology.

Chip

Applications

Basic, Discovery
& Translational Research

Molecular Diagnostics

Genome Sequencing

Applied Markets

About News Partners Investors Careers Contact

Chip

Applications

Basic, Discovery
& Translational Research

Molecular Diagnostics

we are

True Game Changers

Our Vision: Digitizing Biology to Transform Health

Roswell was founded in 2014 by veterans of genomic sequencing who understood that precision medicine would fail to live up to its promise without a new technology. If digitizing cell phones could radically transform the way we live, what could we do if we digitized biology? With this vision, Paul Mola and Barry Merriman set out to develop the first molecular electronics chip to digitize biology and transform health.

Devices informed by a dynamic knowledge base will modernize diagnostics and disease surveillance by moving testing from labs into the hands of individuals

Unique mobile users